🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

5,027 results for “ERA” Clear

  1. Erlotinib

    United Therapeutics Europe Ltd

    Lung Cancer

    phase 2 small molecule completed

    1 trial

  2. Etanercept

    United Therapeutics Europe Ltd

    Lupus Erythematosus, Discoid

    phase 2 small molecule completed

    1 trial

  3. Eteplirsen

    Sarepta Therapeutics

    Duchenne Muscular Dystrophy

    phase 2 small molecule terminated

    2 trials

  4. Etirinotecan pegol

    Nektar Therapeutics UK Limited

    Anaplastic Astrocytomas

    phase 2 small molecule completed

    1 trial

  5. Etrasimod

    Arena Pharmaceutical Enterprises Limited

    Ulcerative Colitis

    phase 2 small molecule completed

    1 trial

  6. Etrinabdione oral solution

    Wuhan Createrna Science and Technology Co., Ltd

    Peripheral Arterial Disease

    phase 2 small molecule active

    1 trial

  7. Evaluation of 64Cu-ATSM PET/CT as a predictor of response to neoadjuvant therapy in locally advanced rectal cancer (TEP-64Cu-ATSM-Rectum)

    CERO THERAPEUTICS HOLDINGS, INC.

    Rectal adenocarcinoma

    phase 2 other active

    1 trial

  8. Exercise Programme

    United Therapeutics Europe Ltd

    Parkinson's Disease

    phase 2 other completed

    1 trial

  9. Exercise Training

    United Therapeutics Europe Ltd

    Breast Cancer

    phase 2 other completed

    1 trial

  10. Exicorilant

    CORCEPT THERAPEUTICS INC

    Metastatic Castration-Resistant Prostate Cancer

    phase 2 small molecule terminated

    1 trial

  11. Experimental 1 - DBS of bilateral NAc - 6 months of active stimulation -- > 6 months of sham stimulation

    BRIGHT MINDS BIOSCIENCES INC.

    Methamphetamine Use Disorder

    phase 2 other active

    1 trial

  12. Extended Access of Momelotinib for Subjects with Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ETMF)

    GlaxoSmithKline

    Primary Myelofibrosis (PMF), Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)

    phase 2 other active

    1 trial

  13. Extended-release Onapristone

    Context Therapeutics

    Refractory Endometrial Adenocarcinoma

    phase 2 small molecule active

    1 trial

  14. Ezutromid

    Summit Therapeutics

    Duchenne Muscular Dystrophy

    phase 2 small molecule terminated

    1 trial

  15. FCD105

    VYNE Therapeutics

    Acne Vulgaris

    phase 2 other completed

    1 trial

  16. FDX104 (4% Doxycycline)

    VYNE Therapeutics

    Rash Due to Epidermal Growth Factor Receptor Inhibitors

    phase 2 small molecule completed

    1 trial

  17. FGF-2

    United Therapeutics Europe Ltd

    Tympanic Membrane Perforation

    phase 2 small molecule completed

    1 trial

  18. FHD-286

    Foghorn Therapeutics

    Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  19. FLUDARABINE PHOSPHATE, ALDESLEUKIN, LN-145, FLUDARABINE PHOSPHATE, CYCLOPHOSPHAMIDE

    Iovance Biotherapeutics B.V.

    Recurrent, metastatic, or persistent Cervical Carcinoma

    phase 2 small molecule active

    1 trial

  20. FMP2.1/AS01B

    United Therapeutics Europe Ltd

    Plasmodium Falciparum Malaria

    phase 2 mab completed

    1 trial

  21. FMX-103 1.5%

    VYNE Therapeutics

    Rosacea

    phase 2 small molecule completed

    1 trial

  22. FMX114

    VYNE Therapeutics

    Atopic Dermatitis

    phase 2 small molecule completed

    1 trial

  23. FOLFIRNINOX

    ACTUATE THERAPEUTICS, INC.

    Pancreatic Adenocarcinoma

    phase 2 small molecule active

    1 trial

  24. FOLINATE DE CALCIUM HIKMA 10 mg/mL, solution injectable/pour perfusion, Vectibix 20 mg/ml concentrate for solution for infusion, Fluorouracilo Accord 50 mg/ml solución inyectable o para perfusión EFG, Fluorouracil Accord 50 mg/ml Injektions-/ Infusionslösung, Fluorouracile AHCL 50 mg/ml, Soluzione per iniezione o infusione, SOTORASIB, FLUOROURACILE ACCORD 50 mg/ml, solution à diluer pour perfusion, Fluorouracilo Accord 50 mg/ml solución inyectable o para perfusión EFG, FLUOROURACILE ACCORD 50 mg/ml, solutio

    CERO THERAPEUTICS HOLDINGS, INC.

    colorectal cancer

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources